Trial Profile
A Phase II Trial of Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 29 Jan 2024 Planned End Date changed from 31 Mar 2024 to 30 Jun 2024.
- 29 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Mar 2024.
- 16 Oct 2023 Planned End Date changed from 30 Sep 2023 to 31 Mar 2024.